Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prescription Drugs | 22 | 2023 | 595 | 8.830 |
Why?
|
Drug Costs | 33 | 2024 | 1105 | 8.570 |
Why?
|
Drugs, Generic | 19 | 2023 | 421 | 6.360 |
Why?
|
Drug Approval | 13 | 2023 | 742 | 3.670 |
Why?
|
Medicaid | 12 | 2024 | 2736 | 3.060 |
Why?
|
Medicare Part D | 9 | 2023 | 328 | 2.750 |
Why?
|
Drug Industry | 12 | 2024 | 746 | 2.670 |
Why?
|
Pharmacy | 3 | 2024 | 91 | 2.500 |
Why?
|
Orphan Drug Production | 3 | 2024 | 50 | 1.970 |
Why?
|
Pharmacies | 3 | 2024 | 150 | 1.880 |
Why?
|
Medicare Part B | 3 | 2023 | 108 | 1.830 |
Why?
|
Inflation, Economic | 2 | 2023 | 28 | 1.820 |
Why?
|
Economic Competition | 5 | 2022 | 214 | 1.820 |
Why?
|
United States | 59 | 2024 | 69872 | 1.330 |
Why?
|
Medicare | 12 | 2024 | 6566 | 1.170 |
Why?
|
Health Expenditures | 9 | 2024 | 2348 | 1.050 |
Why?
|
Federal Government | 2 | 2023 | 260 | 1.010 |
Why?
|
Insurance, Pharmaceutical Services | 4 | 2023 | 336 | 0.930 |
Why?
|
Hiccup | 1 | 2023 | 9 | 0.930 |
Why?
|
Legislation, Drug | 3 | 2023 | 206 | 0.920 |
Why?
|
Device Approval | 3 | 2014 | 163 | 0.910 |
Why?
|
Policy | 2 | 2024 | 508 | 0.900 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2024 | 397 | 0.890 |
Why?
|
United States Food and Drug Administration | 10 | 2022 | 1584 | 0.890 |
Why?
|
Cost Savings | 3 | 2023 | 926 | 0.870 |
Why?
|
Citric Acid | 1 | 2023 | 126 | 0.870 |
Why?
|
Negotiating | 4 | 2024 | 133 | 0.850 |
Why?
|
Pharmaceutical Services | 1 | 2023 | 140 | 0.830 |
Why?
|
Drug Substitution | 2 | 2022 | 281 | 0.810 |
Why?
|
Deductibles and Coinsurance | 2 | 2021 | 316 | 0.800 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2024 | 256 | 0.790 |
Why?
|
Herpes Zoster Vaccine | 1 | 2021 | 47 | 0.780 |
Why?
|
Commerce | 2 | 2023 | 592 | 0.760 |
Why?
|
Vasopressins | 1 | 2022 | 370 | 0.760 |
Why?
|
Anti-Obesity Agents | 1 | 2024 | 217 | 0.750 |
Why?
|
Hydroxychloroquine | 2 | 2021 | 412 | 0.750 |
Why?
|
Immunization Schedule | 1 | 2021 | 221 | 0.740 |
Why?
|
Herpes Zoster | 1 | 2021 | 264 | 0.680 |
Why?
|
Drug Evaluation | 1 | 2020 | 647 | 0.650 |
Why?
|
Drug Utilization | 2 | 2021 | 1183 | 0.630 |
Why?
|
Abortion, Induced | 1 | 2023 | 458 | 0.610 |
Why?
|
Multiple Sclerosis | 2 | 2024 | 3079 | 0.600 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 13695 | 0.580 |
Why?
|
Quality-Adjusted Life Years | 1 | 2023 | 1683 | 0.570 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 689 | 0.570 |
Why?
|
Costs and Cost Analysis | 5 | 2024 | 1681 | 0.570 |
Why?
|
Motivation | 2 | 2023 | 1971 | 0.540 |
Why?
|
Hepatitis C, Chronic | 1 | 2024 | 1031 | 0.530 |
Why?
|
Anti-Infective Agents | 1 | 2023 | 972 | 0.530 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2022 | 643 | 0.530 |
Why?
|
Vaccines | 1 | 2024 | 822 | 0.510 |
Why?
|
Humans | 69 | 2024 | 744343 | 0.490 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7181 | 0.490 |
Why?
|
Defibrillators, Implantable | 2 | 2014 | 1440 | 0.480 |
Why?
|
Influenza Vaccines | 1 | 2021 | 738 | 0.480 |
Why?
|
Hepatitis C | 1 | 2024 | 1591 | 0.460 |
Why?
|
Antirheumatic Agents | 1 | 2023 | 1339 | 0.450 |
Why?
|
Insurance Coverage | 2 | 2024 | 1901 | 0.450 |
Why?
|
Marketing | 4 | 2023 | 212 | 0.440 |
Why?
|
Health Care Reform | 1 | 2022 | 1261 | 0.440 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2014 | 430 | 0.430 |
Why?
|
Medication Adherence | 2 | 2021 | 2063 | 0.430 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2727 | 0.430 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 25043 | 0.390 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5137 | 0.390 |
Why?
|
Insulin | 2 | 2023 | 6580 | 0.380 |
Why?
|
Osteoarthritis, Knee | 7 | 2014 | 1222 | 0.380 |
Why?
|
Prescription Fees | 2 | 2022 | 146 | 0.370 |
Why?
|
Influenza, Human | 1 | 2021 | 1479 | 0.370 |
Why?
|
Prescriptions | 2 | 2022 | 387 | 0.350 |
Why?
|
Pacemaker, Artificial | 1 | 2014 | 816 | 0.310 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4149 | 0.300 |
Why?
|
Insurance Claim Review | 2 | 2021 | 720 | 0.280 |
Why?
|
Neoplasms | 3 | 2023 | 21683 | 0.270 |
Why?
|
Rare Diseases | 2 | 2024 | 553 | 0.270 |
Why?
|
Hospitals | 1 | 2019 | 3952 | 0.270 |
Why?
|
Aged | 20 | 2024 | 163280 | 0.270 |
Why?
|
Arthroplasty, Replacement, Knee | 5 | 2014 | 1458 | 0.250 |
Why?
|
Heart Valve Prosthesis | 1 | 2014 | 1488 | 0.250 |
Why?
|
Pharmaceutical Preparations | 2 | 2023 | 1071 | 0.240 |
Why?
|
Legislation as Topic | 1 | 2023 | 80 | 0.220 |
Why?
|
Citrates | 1 | 2023 | 131 | 0.220 |
Why?
|
Equipment Safety | 2 | 2014 | 264 | 0.220 |
Why?
|
Catechols | 1 | 2022 | 61 | 0.220 |
Why?
|
Biological Factors | 1 | 2024 | 164 | 0.220 |
Why?
|
Electronic Health Records | 1 | 2019 | 4468 | 0.220 |
Why?
|
Mifepristone | 1 | 2023 | 150 | 0.220 |
Why?
|
Burnout, Professional | 2 | 2022 | 694 | 0.220 |
Why?
|
Antisocial Personality Disorder | 1 | 2023 | 228 | 0.210 |
Why?
|
European Union | 1 | 2023 | 158 | 0.210 |
Why?
|
Cardiology | 1 | 2014 | 1668 | 0.210 |
Why?
|
Cohort Studies | 6 | 2024 | 40561 | 0.210 |
Why?
|
Drug Labeling | 2 | 2021 | 233 | 0.210 |
Why?
|
Patents as Topic | 1 | 2023 | 103 | 0.210 |
Why?
|
Atrial Fibrillation | 1 | 2021 | 5034 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.200 |
Why?
|
State Government | 1 | 2024 | 372 | 0.190 |
Why?
|
Pharmacy Service, Hospital | 1 | 2022 | 133 | 0.190 |
Why?
|
Pharmacists | 1 | 2022 | 248 | 0.180 |
Why?
|
National Health Programs | 1 | 2023 | 445 | 0.170 |
Why?
|
Time Factors | 7 | 2023 | 40075 | 0.170 |
Why?
|
Cost Control | 1 | 2021 | 624 | 0.170 |
Why?
|
Knee Prosthesis | 2 | 2013 | 425 | 0.170 |
Why?
|
Chloroquine | 1 | 2020 | 280 | 0.160 |
Why?
|
Off-Label Use | 1 | 2020 | 169 | 0.160 |
Why?
|
Stroke | 1 | 2021 | 9981 | 0.160 |
Why?
|
Antithrombins | 1 | 2021 | 304 | 0.160 |
Why?
|
Drugs, Investigational | 1 | 2020 | 214 | 0.160 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15165 | 0.150 |
Why?
|
Cost Sharing | 1 | 2021 | 407 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 246 | 0.150 |
Why?
|
Databases, Factual | 3 | 2021 | 7729 | 0.150 |
Why?
|
Nitriles | 1 | 2022 | 956 | 0.150 |
Why?
|
Pandemics | 3 | 2023 | 8388 | 0.150 |
Why?
|
Sample Size | 1 | 2021 | 845 | 0.150 |
Why?
|
Policy Making | 1 | 2021 | 554 | 0.150 |
Why?
|
California | 1 | 2021 | 1402 | 0.150 |
Why?
|
Hepacivirus | 1 | 2024 | 1379 | 0.140 |
Why?
|
HIV Infections | 1 | 2023 | 16718 | 0.140 |
Why?
|
Government Regulation | 1 | 2021 | 522 | 0.140 |
Why?
|
Medicare Part C | 1 | 2021 | 296 | 0.140 |
Why?
|
Pyridones | 1 | 2021 | 712 | 0.140 |
Why?
|
United States Department of Veterans Affairs | 1 | 2020 | 875 | 0.130 |
Why?
|
Disclosure | 1 | 2021 | 736 | 0.130 |
Why?
|
Biological Products | 1 | 2023 | 860 | 0.120 |
Why?
|
Drug Prescriptions | 2 | 2021 | 1637 | 0.120 |
Why?
|
Physicians, Women | 1 | 2020 | 486 | 0.120 |
Why?
|
Consensus | 1 | 2023 | 2959 | 0.120 |
Why?
|
Medicine | 1 | 2022 | 946 | 0.120 |
Why?
|
Thiazoles | 1 | 2021 | 1483 | 0.110 |
Why?
|
Anti-Retroviral Agents | 1 | 2023 | 1715 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7913 | 0.110 |
Why?
|
Warfarin | 1 | 2021 | 1496 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4933 | 0.100 |
Why?
|
Cost-Benefit Analysis | 3 | 2021 | 5391 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1380 | 0.100 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 1596 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2024 | 2987 | 0.100 |
Why?
|
Internship and Residency | 2 | 2022 | 5788 | 0.100 |
Why?
|
France | 2 | 2023 | 517 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 1972 | 0.090 |
Why?
|
Prosthesis Failure | 2 | 2013 | 1206 | 0.090 |
Why?
|
Female | 13 | 2024 | 380194 | 0.090 |
Why?
|
Double-Blind Method | 1 | 2023 | 12026 | 0.080 |
Why?
|
Physical Therapy Modalities | 1 | 2013 | 550 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2759 | 0.080 |
Why?
|
Pyridines | 1 | 2021 | 2825 | 0.080 |
Why?
|
Middle Aged | 11 | 2024 | 213383 | 0.080 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 2872 | 0.080 |
Why?
|
Male | 12 | 2024 | 350118 | 0.070 |
Why?
|
Range of Motion, Articular | 1 | 2014 | 1578 | 0.070 |
Why?
|
Postoperative Care | 1 | 2013 | 1486 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 9274 | 0.070 |
Why?
|
Adult | 7 | 2023 | 214055 | 0.070 |
Why?
|
Anticoagulants | 1 | 2021 | 4599 | 0.070 |
Why?
|
Longevity | 1 | 2013 | 1070 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3507 | 0.060 |
Why?
|
Life Expectancy | 1 | 2011 | 1184 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3158 | 0.060 |
Why?
|
Physicians | 1 | 2022 | 4567 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2021 | 57776 | 0.060 |
Why?
|
Pain, Postoperative | 1 | 2013 | 1643 | 0.060 |
Why?
|
Pregnancy | 1 | 2023 | 29144 | 0.050 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2021 | 38 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5751 | 0.050 |
Why?
|
Investments | 1 | 2023 | 143 | 0.050 |
Why?
|
Germany | 1 | 2023 | 862 | 0.050 |
Why?
|
Formularies as Topic | 1 | 2020 | 91 | 0.040 |
Why?
|
New York | 1 | 2021 | 886 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2021 | 601 | 0.040 |
Why?
|
Insurance Benefits | 1 | 2020 | 183 | 0.040 |
Why?
|
Canada | 1 | 2023 | 2065 | 0.040 |
Why?
|
Research Design | 1 | 2013 | 5987 | 0.040 |
Why?
|
Risk Assessment | 2 | 2019 | 23338 | 0.040 |
Why?
|
Models, Statistical | 1 | 2011 | 5102 | 0.040 |
Why?
|
Uncertainty | 1 | 2021 | 734 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 10900 | 0.030 |
Why?
|
Hospital Costs | 1 | 2022 | 985 | 0.030 |
Why?
|
Boston | 2 | 2019 | 9313 | 0.030 |
Why?
|
Pain Measurement | 2 | 2013 | 3420 | 0.030 |
Why?
|
Recovery of Function | 2 | 2013 | 2925 | 0.030 |
Why?
|
Reoperation | 2 | 2013 | 4201 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 426 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8642 | 0.020 |
Why?
|
Age Factors | 3 | 2013 | 18370 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6895 | 0.020 |
Why?
|
Menisci, Tibial | 1 | 2013 | 269 | 0.020 |
Why?
|
Telephone | 1 | 2013 | 617 | 0.020 |
Why?
|
Risk | 2 | 2013 | 9687 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 12745 | 0.020 |
Why?
|
Models, Economic | 1 | 2013 | 713 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 77449 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8663 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14722 | 0.020 |
Why?
|
Research | 1 | 2017 | 1999 | 0.020 |
Why?
|
Knee Injuries | 1 | 2013 | 490 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2518 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1797 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2023 | 13033 | 0.020 |
Why?
|
Sex Distribution | 1 | 2013 | 2297 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2902 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3114 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2019 | 63114 | 0.020 |
Why?
|
Knee Joint | 1 | 2014 | 1680 | 0.020 |
Why?
|
Orthopedics | 1 | 2014 | 904 | 0.020 |
Why?
|
Cost of Illness | 1 | 2013 | 1859 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3558 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3396 | 0.010 |
Why?
|
Health Care Costs | 1 | 2013 | 3209 | 0.010 |
Why?
|
Risk Factors | 2 | 2019 | 72290 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6196 | 0.010 |
Why?
|
Quality Improvement | 1 | 2013 | 3749 | 0.010 |
Why?
|
Comorbidity | 1 | 2011 | 10388 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2013 | 13989 | 0.010 |
Why?
|
Models, Biological | 1 | 2013 | 9583 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13284 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15540 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15226 | 0.010 |
Why?
|
Incidence | 1 | 2013 | 20947 | 0.010 |
Why?
|
Quality of Life | 1 | 2013 | 12804 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15295 | 0.010 |
Why?
|
Prospective Studies | 1 | 2014 | 53288 | 0.010 |
Why?
|
Adolescent | 1 | 2012 | 85781 | 0.000 |
Why?
|
Concepts
(225)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(81)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_